Desmoid Tumors- Pipeline Insight, 2023

Desmoid Tumors- Pipeline Insight, 2023

DelveInsight’s, “Desmoid Tumors- Pipeline Insight, 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Desmoid Tumors: Understanding

Desmoid Tumors: Overview

Desmoid tumors is an abnormal growth that arises from connective tissue. “Desmoid"""" comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis. Desmoid tumors often appear as infiltrative, usually well-differentiated, firm overgrowths of fibrous tissue, and they are locally aggressive. Desmoid tumors can occur in any part of body but most often occur in the abdomen, arms and legs. These are generally not considered cancerous (malignant) because they do not spread to other parts of the body (metastasize); however, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. Desmoid tumors occur frequently in people with an inherited form of colon cancer called familial adenomatous polyposis.

Symptoms

The symptoms of Desmoid Tumors include:

A mass or area of swelling

Pain

Loss of function in the affected area

Pain and obstruction of the bowels

Cramping and nausea, when desmoid tumors occur in the abdomen

Diagnosis

A diagnosis of Desmoid Tumors is based upon a thorough physical examination and specialized tests. Test like imaging tests, such as CT and MRI are done. Biopsy is done to make a definitive diagnosis. Antibodies are often examined in desmoid tumors, including smooth muscle actin, desmin and KIT, to aid in distinguishing them from other tumors.

Treatment

Some desmoid tumors are slow growing and don't require immediate treatment. Others that grow quickly are treated with surgery, radiation therapy, chemotherapy including anticancer drugs, cryoablation or through combinatorial therapy. Anti-inflammatory drugs may cause the tumor to slowly shrink. Chemotherapy agents used to inhibit growth include Doxorubicin (Adriamycin, Rubex), Dacarabazine (DTIC-Dome) and Carboplatin (Paraplatin). Gleevec and Sorafenib are the two kinase inhibitors that are useful in treating desmoid tumors.

""Desmoid Tumors- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Desmoid Tumors pipeline landscape is provided which includes the disease overview and Desmoid Tumors treatment guidelines. The assessment part of the report embraces, in depth Desmoid Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Desmoid Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Desmoid Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Desmoid Tumors.

Desmoid Tumors Emerging Drugs Chapters

This segment of the Desmoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Desmoid Tumors Emerging Drugs

Nirogacestat: SpringWorks Therapeutics

Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor. It is currently in NDA phase of clinical development for patients with desmoid tumors. Desmoid tumors are rare and often debilitating and disfiguring soft tissue tumors for which there are currently no FDA-approved therapies. SpringWorks has a New Drug Application (NDA) under review by the FDA for nirogacestat for the treatment of adults with desmoid tumors, which is being reviewed under the FDA’s Real-Time Oncology Review (RTOR) program. Nirogacestat has received Orphan Drug Designation, Fast Track and Breakthrough Therapy Designations for this indication.

Tegavivint: Iterion Therapeutics

Tegavivint is a potent and selective inhibitor of nuclear β-catenin that binds to TBL1 (Transducin βeta-like Protein One). This enables specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions and thus avoids toxicity issues common to other drugs in this pathway. Tegavivint is currently in Phase IIa clinical trial in progressive desmoid tumors after establishing safety and initial clinical efficacy in Phase I study.

Further product details are provided in the report……..

Desmoid Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Desmoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Desmoid Tumors

There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i.e. NDA include, SpringWorks Therapeutics.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Desmoid Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Desmoid Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Desmoid Tumors drugs.

Desmoid Tumors Report Insights

Desmoid Tumors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Desmoid Tumors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Desmoid Tumors drugs?

How many Desmoid Tumors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Desmoid Tumors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Desmoid Tumors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Desmoid Tumors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Ayala Pharmaceuticals, Inc,

SpringWorks Therapeutics

Recursion Pharmaceuticals Inc.

Iterion Therapeutics

180 Life Sciences

AFT Pharma

Timber Pharmaceuticals

MedPact

Intas Pharmaceutical

Jina pharmaceuticals

Key Products

AL102

Nirogacestat oral tablet

REC-4881

Tegavivint